Drug Profile
Research programme: allosteric kinase inhibitors - Kemia
Latest Information Update: 06 Dec 2010
Price :
$50
*
At a glance
- Originator Kemia
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 27 Feb 2008 Research programme is available for licensing in USA (http://www.kemia.com)
- 27 Feb 2008 Early research in Undefined indication in USA (unspecified route)